The IL-17/ IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).
Galluzzo, M., D'Adamio, S., Massaro, A., Piccolo, A., Bianchi, L., Talamonti, M. (2019). Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date. CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 12, 311-321 [10.2147/CCID.S165605].
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
Galluzzo, M
Writing – Original Draft Preparation
;Bianchi, L;Talamonti, M
2019-01-01
Abstract
The IL-17/ IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).File | Dimensione | Formato | |
---|---|---|---|
30-apr-2019-ccid-165605-spotlight-on-brodalumab-in-the-treatment-of-plaque-psoriasis.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
466.61 kB
Formato
Adobe PDF
|
466.61 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.